Elevation Oncology, Inc.
DelistedCIK 1783032fmd_1F2Y01GJCE1DK0GJ0RS5SRQNMRManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Mar 31, 2025, 20 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Research and development | 15 | 24 | 79 | 25 | 29 |
| Total operating expenses | 17 | 32 | 95 | 45 | 45 |
| Operating income | (17) | (32) | (95) | (45) | (45) |
| Interest expense | – | – | 2 | 4 | 4 |
| Other non-operating income (expense) | 0 | 0 | (1) | (0) | 0 |
| Income before taxes | – | (32) | (95) | (46) | (44) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | (32) | (95) | (46) | (44) |
| Net income | (17) | (32) | (95) | (46) | (44) |